MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
*Driving Forces: Market Research, Intelligence, Analysis, Datapoints, Databases & Trends
2023: Top 20 Genomics Companies in the World
Myriad Genetics Incorporated (NASDAQ: MYGN)
Organization & Developments: Myriad
Parents
Myriad Genetics Incorporated (NASDAQ: MYGN)
Children
*Has a test 46-gene test that is used after men have their prostate tumors surgically removed to tell whether they are at risk of recurrence.
*Myriad Genetics received its first neuroscience diagnostic through the acquisition of Assurex Health. The GeneSight diagnostic, which was developed by Assurex, is a genetic test for psychotropic medicine selection. Salt Lake City, UT-based Myriad said the market potential for the test could well exceed $4 billion.
2014: In Myriad’s $270M deal for Crescendo Bioscience, biotech and digital health converge_medcitynews
2014: Myriad is using its 20 or so collaborations with major pharmaceutical companies to expand its offerings of companion diagnostics, which help identify patients who could benefit from specific drugs, Business Organization: Myriad
2014: The deal propels Myriad, primarily known for its breast cancer tests and the U.S. Supreme Court case that revolved around its ability to patent the gene at the core of those tests, into the area of autoimmune diseases.
2017: Myriad Genetics Makes A Strong Case For Its Prolaris Test - Myriad Genetics, Inc. (NASDAQ:MYGN)
2019: Myriad Genetics's stock surges after FDA approval of diagnostic test for pancreatic cancer
2022: Myriad Genetics, Inc. 2022 Q3 - Results - Earnings Call Presentation_ seekingalpha.com
2022: Myriad: Trying To Find Its Footing In An Evolving Industry_seekingalpha.com
2024: Myriad and Flatiron Integrate Genetic Testing with Electronic Medical Record Platform
2024: Myriad Genetics, Inc. 2023 Q4 - Results - Earnings Call Presentation
2024: Myriad Genetics' Strategic Growth Fuels Bullish Outlook
2024: Myriad weakness due to UnitedHealth coverage update, says Stephens
2025: Myriad Genetics: Navigating Through A Setback
Jumps
*Key People: Myriad
Finance & Acquisition: Myriad